Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
10 8월 2023 - 9:30PM
Orgenesis Inc. (NASDAQ: ORGS)
(“Orgenesis” or the “Company”), a global biotech company working to
unlock the full potential of cell and gene therapies (CGT), today
announced that it will host a conference call at 8:00 AM Eastern
Time on Friday, August 11, 2023, to discuss the company’s corporate
progress and other developments.
The conference call will be available via
telephone by dialing toll free 877-545-0523 for U.S. callers or +1
973-528-0016 for international callers and using entry code 132591.
A webcast of the call may be accessed at
https://www.webcaster4.com/Webcast/Page/2585/48936 or on the
Company’s Investor Events section of the website here.
A webcast replay will be available on the
Company’s Investor Events section of the website
(https://ir.orgenesis.com/events#/) through Sunday, August 11,
2024. A telephone replay of the call will be available
approximately one hour following the call, through Friday, August
25, 2023, and can be accessed by dialing 877-481-4010 for U.S.
callers or +1 919-882-2331 for international callers and entering
conference ID: 48936.
About OrgenesisOrgenesis is a global biotech
company that has been committed to unlocking the potential of
decentralized cell and gene therapies (CGTs) since 2012. Orgenesis
established the POCare Network in 2020 to bring academia,
hospitals, and Industry together to make these innovations more
affordable and accessible to patients. In 2022, the POCare Services
business unit responsible for developing and managing the
decentralized POCare Centers and proprietary OMPULs was formed.
Orgenesis will continue to focus on advancing to market through
various partnerships its CGTs to provide a rapid, globally
harmonized pathway for these therapies to reach and treat large
numbers of patients at lowered costs through efficient, scalable,
and decentralized production. Additional information about the
Company is available at: www.orgenesis.com.
Notice Regarding Forward-Looking
Statements This press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended. These
forward-looking statements involve substantial uncertainties and
risks and are based upon our current expectations, estimates and
projections and reflect our beliefs and assumptions based upon
information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on
our current expectations about future events. These forward-looking
statements are not guarantees of future performance and are subject
to risks, uncertainties and assumptions that are difficult to
predict. Our actual results, performance or achievements could
differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors,
including, but not limited to, our reliance on, and our ability to
grow, our point-of-care cell therapy platform and OMPUL business,
our ability to achieve and maintain overall profitability, our
ability to manage our research and development programs that are
based on novel technologies, our ability to control key elements
relating to the development and commercialization of therapeutic
product candidates with third parties, the timing of completion of
clinical trials and studies, the availability of additional data,
outcomes of clinical trials of our product candidates, the
potential uses and benefits of our product candidates, our ability
to manage potential disruptions as a result of the COVID-19
pandemic, the sufficiency of working capital to realize our
business plans and our ability to raise additional capital, the
development of our POCare strategy, our trans differentiation
technology as therapeutic treatment for diabetes, the technology
behind our in-licensed ATMPs not functioning as expected, our
ability to further our CGT development projects, either directly or
through our JV partner agreements, and to fulfill our obligations
under such agreements, our license agreements with other
institutions, our ability to retain key employees, our competitors
developing better or cheaper alternatives to our products, risks
relating to legal proceedings against us and the risks and
uncertainties discussed under the heading "RISK FACTORS" in Item 1A
of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2022, and in our other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
any forward-looking statement for any reason.
IR contact for Orgenesis:Crescendo
Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com
Communications contact for
OrgenesisIB CommunicationsNeil Hunter / Michelle BoxallTel
+44 (0)20 8943
4685neil@ibcomms.agency / michelle@ibcomms.agency
Orgenesis (NASDAQ:ORGS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Orgenesis (NASDAQ:ORGS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024